Home
About Us
About Boan
Culture
Our History
Our Team
Responsibility
R&D
Technology platform
Boan Product Pipeline
Intellectual Property
Production capacity
Products
News
Careers
People Strategy
Development
Job Opportunities
Investors
Announcement & Circular
Corporate Governance
Financial Results
IR Activities
Contact IR
Contact us
简
/
繁
/
EN
News
Year
2021
2022
2023
2024
2025
2026
Month
1
2
3
4
5
6
7
8
9
10
11
12
2026.11.06
Boan Biotech Receives IND Clearance in China for BA2201, a Novel TL1A/IL-23 Bispecific Antibody for Inflammatory Bowel Disease
2026.10.30
Boan Biotech Enters into Licensing Agreement for Denosumab Injection 60 mg in Japan
2026.10.22
Boan Biotech Announces First Subject Enrolled in Phase I Clinical Trial of BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein) in China
16
2026-09
Boan Biotech Receives IND Clearance in China for BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)
28
2026-08
Boan Biotech Announces 2026 Interim Results
27
2026-08
IND Application for Boan Biotech’s TL1A/IL-23 Bispecific Antibody BA2201 Accepted in China
17
2026-08
Boan Biotech Announces Successful Completion of Phase Ia Clinical Trial of BA1302 (CD228-Directed ADC) in China
06
2026-08
Boan Biotech Submits BLA for Aflibercept Intravitreous Injection in Brazil
08
2026-07
China’s CDE Accepts IND Application for Boan Biotech’s BA1203 (A Masked Anti-PD-1/IL-2 Fusion Protein)
03
2026-07
Boan Biotech Receives CDE Clearance for Phase Ⅱ Clinical Trial of BA1106 in Combination with BA1104 for NSCLC
1
2
3
4
5
Follow me
鲁公网安备37069102000284
ICP备：鲁ICP备2021004064号-1
